At least 2.2 billion people have a vision impairment, and in around 1 billion of those cases it is preventable or still unaddressed. Glaucoma accounts for 7.7 million and diabetic retinopathy 3.9 million, with the burden falling most heavily on low- and middle-income regions.
All 175 lines are sterile ophthalmic presentations, including 16 fixed combinations built on timolol.
Range depth
Full range, fixed combinations included.
Alpha agonists and carbonic anhydrase inhibitors.
15 moxifloxacin presentations.
Preservative-free presentations included.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.